XW033DAIntroduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- Billable / Specific Code
XW033DA is a billable ICD-10-PCS procedure code for Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRGs 673, 674, 675. The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 0 | Introduction |
| 4 | BodyPart | 3 | Peripheral Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | D | Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension |
| 7 | Qualifier | A | New Technology Group 10 |
Code History
- 3E033U1 — Introduce Nonaut Pancr Islet in Periph Vein, Perc
Similar Procedure Codes
Questions About XW033DA
Is XW033DA a billable code?
Yes. XW033DA is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10 on inpatient claims from October 1, 2025 through September 30, 2026.
What do the characters in XW033DA mean?
XW033DA breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 3 is the BodyPart (Peripheral Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character D is the Device/Substance/Technology (Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension); the 7th character A is the Qualifier (New Technology Group 10).
What MS-DRG does XW033DA group to?
On an inpatient stay, Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10 maps to MS-DRGs 673, 674, 675, with relative weights from 1.6414 to 4.2016. The MS-DRG sets the fixed Medicare payment for the stay.
